Hexarelin
aka Examorelin
Mechanism
Hexarelin (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide growth hormone secretagogue developed by Mediolanum (Italy) in the 1990s. It is a potent ghrelin-receptor (GHSR-1a) agonist that also binds the CD36 scavenger receptor, giving it a cardioprotective signal distinct from other GHRPs. It is not FDA-approved for any indication and remains a research-only compound; its clinical development for GH deficiency and cardiac indications did not reach approval. A defining feature versus other GHRPs is rapid, pronounced tachyphylaxis with chronic daily dosing.
Identification
| CAS number | 140703-51-1 |
|---|---|
| Molecular formula | C47H58N12O6 |
| Typical dose | 1–2 mcg/kg subcutaneous (human research studies); 1–100 mcg/kg subcutaneous (animal studies) |
| Half-life | ~76 minutes (IV, pharmacokinetic study) |
Vendors selling Hexarelin
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Moglabs | 5 mg | $38.00 | — | 96 |
| Peptide Tech | 2 mg | $29.99 | — | 94 |
| Skye Peptides | 5 mg | $44.00 | — | 90 |
| Qihang Peptide | — | — | — | 87 |
| Peptidegurus | 2 mg | — | — | 84 |
| Peptidegurus | 5 mg | — | — | 84 |
| MedGe Peptides | 5 mg | $75.00 | — | 82 |
| Nox Amino | 10 mg | $65.00 | — | 55 |
| Peptiatlas | — | — | — | 51 |
| DongCheng Peptide | — | — | — | 46 |
| HongDa Peptide | — | $54.00 | — | 43 |
| zztai Peptide Ltd | — | — | — | 43 |
| MJT peptides | 5 mg | $92.00 | — | 39 |
| Ruo Bio | 5 mg | $36.00 | — | — |
| AMC Essentials | 5 mg | $32.99 | — | — |
| Atomik Labz | 5 mg | $40.00 | — | — |
| Biotech Peptides | 5 mg | $49.00 | — | — |
| Core Peptides | 5 mg | $47.00 | — | — |
| Genetic Peptide | 5 mg | $60.00 | — | — |
| Genetic Peptide | 10 mg | $60.00 | — | — |
| Genetic Peptide | 15 mg | $60.00 | — | — |
| Kimera Chems | — | $46.99 | — | — |
| Modern Research Peptides | 2 mg | $27.99 | — | — |
| Paramount Peptides | 5 mg | $47.00 | — | — |
| Solution Peptides | 5 mg | $40.00 | — | — |
Research
Objective Hexarelin is a growth hormone secretagogue receptor type 1a agonist with a potent anti-apoptotic effect. We studied the neuroprotective effect of hexarelin on the survival of retinal ganglion cells (RGCs) in the retina following optic nerve transection (ONT).
source →Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.
source →Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.
source →Alexamorelin is a synthetic peptide and growth hormone secretagogue (GHS) with potential performance-enhancing properties, making its use and abuse a topic of interest in clinical research and doping monitoring.
source →Platinum-based chemotherapeutics, particularly cisplatin, are crucial in the treatment of various malignancies due to their strong antitumor effects. However, a significant side effect of cisplatin is muscle atrophy, which severely impairs physical strength, diminishes quality of life and complicates cancer therapy.
source →The scientific and medical community faced an unprecedented global health hazard that led to nearly 7 million deaths attributable to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
source →CD36 is a highly glycosylated integral membrane protein that belongs to the scavenger receptor class B family and regulates the pathological progress of metabolic diseases.
source →Introduction Hexarelin exhibits significant protection against organ injury in models of ischemia/reperfusion (I/R)-induced injury (IRI). Nevertheless, the impact of Hexarelin on acute kidney injury (AKI) and its underlying mechanism remains unclear.
source →Amyotrophic lateral sclerosis (ALS) is an incurable motor neuron disease whose etiology remains unresolved; nonetheless, mutations of superoxide dismutase 1 (SOD1) have been associated with several variants of ALS.
source →Permeability enhancer-based formulations offer a promising approach to enhance the oral bioavailability of peptides.
source →Hexarelin, a synthetic growth hormone-releasing peptide, is shown to be protective in cardiovascular diseases such as myocardial infraction and atherosclerosis. However, the functional role of hexarelin in abdominal aortic aneurysm (AAA) remains undefined.
source →The majority of the conventional techniques that are utilized for investigating the pathogenesis of cardiovascular disease in preclinical animal models do not permit microlevel assessment of in situ cardiomyocyte and microvascular functions.
source →